Global X Genomics & Biotechnology ETF
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $85,812,000 last year. Net change in cash is therefore $8,156,000.
Cash Flow
| 2011 | -50.51M | -27.14M | 85.81M |
|---|
GNOM Cash Flow Statement (2011 – 2011)
| 2011 | |
|---|---|
Cash at beginning of period | 68.91M |
Operating activities | |
Net income | -72.34M |
| Adjustments to reconcile net income to cash generated by operating activities: | |
Depreciation and amortization | 11.71M |
Stock-based compensation expense | 4.32M |
| Deferred income tax benefit | 4.32M |
| Changes in operating assets and liabilities: | |
Accounts receivable, net | -1.58M |
Inventories | -1.07M |
Accounts payable | 1.22M |
Cash generated by operating activities | -50.51M |
Investing activities | |
Purchases Of Investments | 0 |
Investments In Property Plant And Equipment | -20.39M |
Acquisitions Net | 0 |
Cash generated by investing activities | -27.14M |
Financing activities | |
Common Stock Issued | 73.93M |
Payments for dividends | 0 |
Repurchases of common stock | -77.07M |
Repayments of term debt | 0 |
Cash used in financing activities | 85.81M |
Net Change In Cash | 8.15M |
Cash at end of period | 77.07M |
| Data source |